<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00763204</url>
  </required_header>
  <id_info>
    <org_study_id>AN2728-PSR-103</org_study_id>
    <secondary_id>2007-006600-37</secondary_id>
    <secondary_id>C3291022</secondary_id>
    <nct_id>NCT00763204</nct_id>
  </id_info>
  <brief_title>A Phase I Study to Assess Novel Cream in a Psoriasis Plaque Test</brief_title>
  <official_title>A Phase I, Randomized, Observer-blind, Single-center, Vehicle- And Comparator-controlled, Initial Dose-ranging Study To Assess The Antipsoriatic Efficacy Of Different Concentrations Of An2728 Cream In A Psoriasis Plaque Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate dose-response relationship, antipsoriatic&#xD;
      efficacy and safety of different concentrations of topical formulations with AN2728 in&#xD;
      subjects with psoriasis vulgaris.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be performed in 12 male subjects with stable psoriatic plaques. The study&#xD;
      preparations and the comparator will be tested observer-blind. Treatments will be randomly&#xD;
      assigned to the test fields. All subjects will receive all treatments, with intraindividual&#xD;
      comparison of the treatments.&#xD;
&#xD;
      Altogether six test fields will be examined per subject (four active AN2728 creams of&#xD;
      different concentrations: 2 %, 1 %, 0.3 %, 0.03 %, the active ingredient-free vehicle, and a&#xD;
      marketed corticoid preparation). The test fields will be treated occlusively over a study&#xD;
      period of 12 days. Topical application of approximately 200 uL of each assigned intervention&#xD;
      is administered per treatment, for a total of 10 treatments over a 12-day treatment period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 29, 2008</start_date>
  <completion_date type="Actual">March 7, 2008</completion_date>
  <primary_completion_date type="Actual">March 7, 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of the active study preparations compared to the corresponding vehicle using differences in infiltrate thickness on study day 12.</measure>
    <time_frame>Day 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in infiltrate thickness</measure>
    <time_frame>Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sonographic measurements of infiltrate thickness</measure>
    <time_frame>Day 8, Day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The AUC of the infiltrate thickness</measure>
    <time_frame>Day 8, Day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical assessment scores for assessment of efficacy</measure>
    <time_frame>Day 8, Day 12</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AN2728 Cream, 2%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AN2728 Cream, 1%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AN2728 Cream, 0.3%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>AN2728 Cream Vehicle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Betnesol®-V Creme (betamethasone 0.1 %)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AN2728 Cream, 2%</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AN2728 Cream, 1%</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AN2728 Cream, 0.3%</intervention_name>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AN2728 Cream Vehicle</intervention_name>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betnesol®-V Creme, 0.1%</intervention_name>
    <arm_group_label>5</arm_group_label>
    <other_name>betamethasone 0.1%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  male subjects aged 18 years or older&#xD;
&#xD;
          -  subjects with psoriasis vulgaris in a chronic stable phase and stable plaques with an&#xD;
             area sufficient for five treatment fields&#xD;
&#xD;
          -  the physical examination must be without disease findings unless the investigator&#xD;
             considers an abnormality to be irrelevant to the outcome of the study&#xD;
&#xD;
          -  written informed consent obtained&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  subjects with psoriasis guttata or pustular psoriasis&#xD;
&#xD;
          -  subjects who require systemically acting medications for the treatment of psoriasis,&#xD;
             which might counter or influence the study objectives, e.g. corticosteroids,&#xD;
             cytostatics&#xD;
&#xD;
          -  local treatment with antipsoriatics (like vitamin D, dithranol, glucocorticosteroids;&#xD;
             except for salicyclic acid in vaseline) in the 4 weeks preceding and during the study;&#xD;
             and any antipsoriatic treatment on the plaques (including corticosteroids, except for&#xD;
             salicyclic acid) in the 8 weeks preceding and during the study.&#xD;
&#xD;
          -  systemic treatment with antipsoriatics in the three months preceding and during the&#xD;
             study&#xD;
&#xD;
          -  treatment with systemic or locally acting medications which might counter or influence&#xD;
             the study aim (e.g. MAO inhibitors, anti-epileptic drugs, anti-psychotic drugs) or&#xD;
             medications which are known to provoke or aggravate psoriasis, e.g. Beta-blocker,&#xD;
             antimalarial drugs and lithium drugs within two weeks before the beginning of the&#xD;
             study and during the study.&#xD;
&#xD;
          -  known allergic reactions to the active ingredients or other components of the study&#xD;
             preparations or comparators&#xD;
&#xD;
          -  blood pressure and heart rate outside the following allowed ranges: systolic blood&#xD;
             pressure 80-160 mm Hg, diastolic blood pressure 60 - 100 mm Hg, heart rate 40-120&#xD;
             beats/min&#xD;
&#xD;
          -  evidence of drug abuse&#xD;
&#xD;
          -  UV-therapy within 4 weeks before beginning and during the study&#xD;
&#xD;
          -  Symptoms of a clinically significant illness that may influenced the outcome of the&#xD;
             study in the 4 weeks before and during the study&#xD;
&#xD;
          -  participation in another clinical trial involving pharmaceutical products in the 4&#xD;
             weeks preceding and during the study&#xD;
&#xD;
          -  in the opinion of the investigator or physician performing the initial examination the&#xD;
             patient should not participate in the study, e.g. due to probable noncompliance or&#xD;
             inability to understand the study and give adequately informed consent&#xD;
&#xD;
          -  subject is institutionalized because of legal or regulatory order&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bioskin GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>September 26, 2008</study_first_submitted>
  <study_first_submitted_qc>September 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2008</study_first_posted>
  <last_update_submitted>February 26, 2019</last_update_submitted>
  <last_update_submitted_qc>February 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Plaque Type Psoriasis</keyword>
  <keyword>Topical</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

